370 related articles for article (PubMed ID: 17661955)
1. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
O'Connor AB; Noyes K; Holloway RG
J Am Geriatr Soc; 2007 Aug; 55(8):1176-84. PubMed ID: 17661955
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
Dakin H; Nuijten M; Liedgens H; Nautrup BP
Clin Ther; 2007 Jul; 29(7):1491-507. PubMed ID: 17825701
[TBL] [Abstract][Full Text] [Related]
5. A cost-utility comparison of four first-line medications in painful diabetic neuropathy.
O'Connor AB; Noyes K; Holloway RG
Pharmacoeconomics; 2008; 26(12):1045-64. PubMed ID: 19014205
[TBL] [Abstract][Full Text] [Related]
6. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Puenpatom RA; Ben-Joseph RH; Summers KH
J Med Econ; 2010; 13(3):482-91. PubMed ID: 20684669
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
Armstrong EP; Malone DC; McCarberg B; Panarites CJ; Pham SV
Curr Med Res Opin; 2011 May; 27(5):939-50. PubMed ID: 21375358
[TBL] [Abstract][Full Text] [Related]
8. Long-term cost-effectiveness of initiating treatment for painful diabetic neuropathy with pregabalin, duloxetine, gabapentin, or desipramine.
Bellows BK; Nelson RE; Oderda GM; LaFleur J
Pain; 2016 Jan; 157(1):203-213. PubMed ID: 26397932
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
[TBL] [Abstract][Full Text] [Related]
10. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy.
Ifuku M; Iseki M; Hidaka I; Morita Y; Komatus S; Inada E
Pain Med; 2011 Jul; 12(7):1112-6. PubMed ID: 21692969
[TBL] [Abstract][Full Text] [Related]
11. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.
Gore M; Sadosky A; Tai KS; Stacey B
Clin Ther; 2007 Aug; 29(8):1655-70. PubMed ID: 17919547
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
Ritchie M; Liedgens H; Nuijten M
Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
[TBL] [Abstract][Full Text] [Related]
13. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
Rodríguez MJ; Díaz S; Vera-Llonch M; Dukes E; Rejas J
Curr Med Res Opin; 2007 Oct; 23(10):2585-96. PubMed ID: 17875242
[TBL] [Abstract][Full Text] [Related]
15. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico.
Arreola Ornelas H; Rosado Buzzo A; García L; Dorantes Aguilar J; Contreras Hernández I; Mould Quevedo JF
Reumatol Clin; 2012; 8(3):120-7. PubMed ID: 22386298
[TBL] [Abstract][Full Text] [Related]
17. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
J Eval Clin Pract; 2012 Dec; 18(6):1170-9. PubMed ID: 21883712
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
Choy E; Richards S; Bowrin K; Watson P; Lloyd A; Sadosky A; Zlateva G
Curr Med Res Opin; 2010 Apr; 26(4):965-75. PubMed ID: 20178405
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin.
Johnson P; Becker L; Halpern R; Sweeney M
Clin Drug Investig; 2013 Jan; 33(1):35-44. PubMed ID: 23179473
[TBL] [Abstract][Full Text] [Related]
20. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
